Results 181 to 190 of about 79,680 (194)

Appetite Suppression by GLP‐1 Receptor Agonists: Role of Delayed Gastric Emptying

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity.
Mark I. Friedman, W. Scott Harmsen, Michael Camilleri   +2 more
wiley   +1 more source

National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017-2024. [PDF]

Medicina (Kaunas)
Car M, Erceg D, Udovičić M, Bokun T, Rahelić D.   +4 more
europepmc   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review. [PDF]

J Clin Med
Caliezi A, Hosseini A, Wolf R, Seyed Jafari SM.   +3 more
europepmc   +1 more source

Preclinical Efficacy and Safety Evaluation of a Novel Controlled‐Expansion ePTFE‐Covered TIPS Stent in a Swine Model

Portal Hypertension &Cirrhosis, EarlyView.
This preclinical study evaluated a novel controlled‐expansion expanded polytetrafluoroethylene (ePTFE)‐covered transjugular intrahepatic portosystemic shunt (TIPS) stent in 11 swine, demonstrating 100% technical success, excellent deployability, and durable 6‐month angiographic patency without thrombosis, migration, fracture, or device‐related toxicity.
Yi Xiang, Qi Zhang, Chuan Liu, Jiawei Zhang, Qingqiao Zhang, Changsheng Shi, Chunze Zhou, Yudong Zhang, Hongliang He, Hao Xie, Hui Shi, Haijian Guo, Wenjing Liu, Muqing Lin, Huajie Yu, Xiaolong Qi   +15 more
wiley   +1 more source

Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension. [PDF]

ERJ Open Res
Aguado B, Lacoste-Palasset T, Ruffenach G, Bauer F, Savale L, Humbert M, Montani D, Antigny F.   +7 more
europepmc   +1 more source

Coronary pericytes as mediators of brain-gut-heart signaling: expanding the cardioprotective paradigm of GLP-1. [PDF]

Ann Med Surg (Lond)
Qamar I, Rehman T, Zehra Rizvi SE, Shehzad Y.   +3 more
europepmc   +1 more source

A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist. [PDF]

Front Pharmacol
Singh A, Shadangi S, Rana S.
europepmc   +1 more source

Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron. [PDF]

ACS Med Chem Lett
Li M, Fang J, Qi G, Guo S, Xu T, Lu Y, Yuan Q, Wang J, Zhu S, Shen J, Yang H, Xie X, Wang K.   +12 more
europepmc   +1 more source